Insider Trading Alert - CGIX, LEA And ANF Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 9, 2015, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $352.00 to $81,483,250.00.

Highlighted Stocks Traded by Insiders:

Cancer Genetics (CGIX) - FREE Research Report

Chaganti Raju S.K., who is Director at Cancer Genetics, sold 24,583 shares at $12.03 on June 9, 2015. Following this transaction, the Director owned 159,394 shares meaning that the stake was reduced by 13.36% with the 24,583-share transaction.

The shares most recently traded at $12.07, up $0.04, or 0.35% since the insider transaction. Historical insider transactions for Cancer Genetics go as follows:

  • 4-Week # shares bought: 10,000
  • 12-Week # shares bought: 10,000
  • 24-Week # shares bought: 61,000

The average volume for Cancer Genetics has been 83,400 shares per day over the past 30 days. Cancer Genetics has a market cap of $118.4 million and is part of the health care sector and health services industry. Shares are up 80.39% year-to-date as of the close of trading on Tuesday.

Cancer Genetics, Inc., an oncology diagnostics company, focuses on developing and commercializing DNA-based tests and services to enhance and personalize the diagnosis, prognosis, and treatment of targeted cancers in the United States, India, and China. Currently, there are 3 analysts who rate Cancer Genetics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CGIX - FREE

TheStreet Quant Ratings rates Cancer Genetics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow, poor profit margins and feeble growth in its earnings per share. Get the full Cancer Genetics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Lear (LEA) - FREE Research Report

Mallett Conrad L Jr, who is Director at Lear, sold 250 shares at $114.59 on June 9, 2015. Following this transaction, the Director owned 4,341 shares meaning that the stake was reduced by 5.45% with the 250-share transaction.

The shares most recently traded at $117.02, up $2.43, or 2.08% since the insider transaction. Historical insider transactions for Lear go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 2,262
  • 12-Week # shares bought: 2,500
  • 12-Week # shares sold: 2,262
  • 24-Week # shares bought: 2,500
  • 24-Week # shares sold: 206,635

The average volume for Lear has been 723,300 shares per day over the past 30 days. Lear has a market cap of $8.9 billion and is part of the consumer goods sector and automotive industry. Shares are up 16.7% year-to-date as of the close of trading on Tuesday.

Lear Corporation designs, develops, engineers, manufactures, assembles, and supplies automotive seating, electrical distribution systems, and related components primarily to automotive original equipment manufacturers worldwide. It operates through two segments, Seating and Electrical. The stock currently has a dividend yield of 0.88%. The company has a P/E ratio of 13.2. Currently, there are 8 analysts who rate Lear a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LEA - FREE

TheStreet Quant Ratings rates Lear as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and attractive valuation levels. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full Lear Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Abercrombie & Fitch (ANF) - FREE Research Report

Angelides Christos E., who is Officer at Abercrombie & Fitch, bought 45,200 shares at $22.16 on June 9, 2015. Following this transaction, the Officer owned 45,200 shares meaning that the stake was boosted by 100% with the 45,200-share transaction.

The shares most recently traded at $22.84, up $0.68, or 2.98% since the insider transaction. Historical insider transactions for Abercrombie & Fitch go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 2,000
  • 12-Week # shares bought: 25,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares bought: 45,000
  • 24-Week # shares sold: 2,000

The average volume for Abercrombie & Fitch has been 2.6 million shares per day over the past 30 days. Abercrombie & Fitch has a market cap of $1.6 billion and is part of the services sector and retail industry. Shares are down 22.49% year-to-date as of the close of trading on Tuesday.

Abercrombie & Fitch Co., through its subsidiaries, operates as a specialty retailer of apparel for men, women, and kids. The company operates through three segments: U.S. Stores, International Stores, and Direct-to-Consumer. The stock currently has a dividend yield of 3.59%. The company has a P/E ratio of 1114.5. Currently, there are 6 analysts who rate Abercrombie & Fitch a buy, 5 analysts rate it a sell, and 13 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANF - FREE

TheStreet Quant Ratings rates Abercrombie & Fitch as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Abercrombie & Fitch Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Liking the Look of Some of These Pullbacks

Liking the Look of Some of These Pullbacks

Heck With the NFL Draft; I'm Anxiously Awaiting a Big Earnings Night

Heck With the NFL Draft; I'm Anxiously Awaiting a Big Earnings Night

Don't Be Surprised If Dip Buyers Jump In on Any Pullback

Don't Be Surprised If Dip Buyers Jump In on Any Pullback

The Best Timeframe Right Now Is the Intraday Trade

The Best Timeframe Right Now Is the Intraday Trade

Health Care Vote Impacts Trump's Deal Maker Image

Health Care Vote Impacts Trump's Deal Maker Image